Table 2.

Adverse events during 48 weeks of treatment

Adverse events	Teriparatide (n = 379) n, %	Alendronate (n = 194) n, %	P value
Any AE	290 (76.52)	124 (63.92)	0.002
Drug-related AEs	181 (47.76)	51 (26.29)	< 0.001
Serious AEs	36 (9.50)	9 (4.64)	0.048
AEs leading to discontinuation of study	9 (2.37)	1 (0.52)	0.176
AEs of interest
Elevated ALP	57 (15.04)	2 (1.03)	< 0.001
Hypercalcemia	38 (10.03)	2 (1.03)	< 0.001
Dizziness	31 (8.18)	6 (3.09)	0.019
Upper respiratory tract infection	30 (7.92)	12 (6.19)	0.452
Hypercholesterolemia	29 (7.65)	17 (8.76)	0.643
Hypertriglyceridemia	23 (6.07)	14 (7.22)	0.597
Arthralgia	21 (5.54)	6 (3.09)	0.019
Back pain	20 (5.28)	7 (3.61)	0.372
Headache	13 (3.43)	4 (2.06)	0.361
Nausea	10 (2.64)	2 (1.03)	0.335
Elevated PTH	6 (1.58)	16 (8.25)	< 0.001
Death	1 (0.26)	0 (0.00)	1.000

PTH parathyroid hormone, ALP alkaline phosphatase